SecBot SecBot
SECBOTREPLAY Home › Report › MIST

MIST · Q3 revenue +73% QoQ, cost cuts

Milestone Pharmaceuticals Inc. · 8-K filed Nov 13, 2026 at 07:36 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Nov 13, 2026 at 07:36 ET

Milestone Pharmaceuticals reported Q3 2026 product revenue of $1.0M, up 73% QoQ, and announced a 30% operating expense reduction to extend cash runway into late 2028, beyond the expected Phase 3 AFib-RVR data readout in 2H 2028. The CFO and CMO have departed, and the company amended its convertible notes to extend the PIK interest period to March 2029.

  • Q3 2026 product revenue $1.0M, up 73% from Q2 2026 ($0.6M)
  • Operating expenses to be reduced by approximately 30%
  • Cash and equivalents $145.4M as of Sep 30, 2026; runway extended into late 2028
  • CFO Amit Hasija and CMO David Bharucha have departed; Anthony Krick named Principal Financial Officer

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access